-
公开(公告)号：EP3318577A1
公开(公告)日：2018-05-09
申请号：EP16818027.1
申请日：2016-06-30
发明人： KUMANOGOH, Atsushi , OMIYA, Ryusuke , TSUNODA, Hiroyuki , BABA, Takeshi , SUZUKI, Sachiyo , TERANISHI, Yuri
IPC分类号： C07K16/28 , A61K39/395 , A61P11/02 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/10 , A61P29/00 , A61P35/00 , A61P37/02 , A61P37/08 , A61P43/00 , C07K16/46 , C12N15/09 , C12P21/08
CPC分类号： A61K39/395 , C07K16/28 , C07K16/2863 , C07K16/46 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2317/75 , C07K2317/76 , C12N15/09
摘要： Provided is a novel anti-Plexin-A1 agonist antibody that promotes dendritic cell contraction. Also provided is a pharmaceutical composition comprising such an antibody and a pharmaceutically acceptable carrier.
摘要翻译： 提供了促进树突细胞收缩的新型抗神经丛素-A1激动剂抗体。 还提供了包含这种抗体和药学上可接受的载体的药物组合物。
-
公开(公告)号：EP3690050A1
公开(公告)日：2020-08-05
申请号：EP18860741.0
申请日：2018-09-27
发明人： TERANISHI, Yuri , KATO, Kazuki , KOGA, Hikaru , IGAWA, Tomoyuki , YAMAGUCHI, Kazuki , SOEDA, Tetsuhiro
IPC分类号： C12N15/13 , A61K39/395 , A61P7/04 , C07K16/36 , C07K16/46 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12P21/08
摘要： Bispecific antibodies whose FIX activation-inhibiting activity is not elevated and whose FVIII cofactor function-substituting activity is elevated have been successfully discovered.
-
公开(公告)号：EP3827024A1
公开(公告)日：2021-06-02
申请号：EP19840512.8
申请日：2019-07-22
-
公开(公告)号：EP3805400A1
公开(公告)日：2021-04-14
申请号：EP19814965.0
申请日：2019-06-03
摘要： In a non-limiting embodiment, the present invention relates to antigen-binding molecules containing an altered TRIM21-binding domain and having an altered cytosolic half-life; pharmaceutical compositions containing such an antigen-binding molecule; methods for using such an antigen-binding molecule; methods for increasing or decreasing the cytosolic half-life of an antigen-binding molecule containing a TRIM21-binding domain; and methods for producing an antigen-binding molecule containing an altered TRIM21-binding domain and having an increased or decreased cytosolic half-life. The present invention also relates to substitutions at specific positions in a TRIM21-binding domain that increase or decrease the cytosolic half-life of an antigen-binding molecule containing a TRIM21-binding domain.
-
公开(公告)号：EP3492496A1
公开(公告)日：2019-06-05
申请号：EP17834452.9
申请日：2017-07-27
发明人： IGAWA, Tomoyuki , TERANISHI, Yuri , KATO, Kazuki , KOGA, Hikaru
摘要： The present invention provides light chain amino acid substitutions that improve the FVIII cofactor function-substituting activity of ACE910 (Emicizumab), novel light chains showing FVIII cofactor function-substituting activity, and heavy chain amino acid substitutions that improve the FVIII cofactor function-substituting activity of novel light chain-containing bispecific antibodies.
-
公开(公告)号：EP3395835A1
公开(公告)日：2018-10-31
申请号：EP16878867.7
申请日：2016-12-22
发明人： IGAWA, Tomoyuki , TERANISHI, Yuri
CPC分类号： A61K39/395 , C07K16/36 , C12N15/02 , C12N15/09 , C12P21/02
摘要： As a result of producing ACE910 variants in which various sites of the constant regions were modified, the inventors discovered bispecific antibodies having FVIII mimetic activity higher than that of ACE910. The inventors also identified mutation positions that elevate the FVIII mimetic activity and discovered methods for elevating the FVIII mimetic activity by using the mutations.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.015 秒)
